Methods for gene editing of targeted sites in cells
The CRISPR/Cas9-based method for site-specific integration in T cells addresses inefficiencies in current gene editing by enhancing homologous recombination, improving manufacturing consistency and therapeutic outcomes.
Patent Information
- Application Number
- JP2023515399
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-10
- Filing Date
- 2021-09-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-09-03
AI Technical Summary
Current gene editing methods, particularly for T cells, face challenges in achieving efficient and precise homologous recombination, leading to issues such as high manufacturing costs, safety concerns from random insertion, and reduced therapeutic efficacy due to non-specific integration.
A method utilizing CRISPR/Cas9 technology for site-specific integration of exogenous sequences into T cells by targeting specific genomic sites like AAVS1, PD1, and TRAC, using gRNA and donor DNA with homology arms to enhance integration efficiency.
Improves the efficiency and homogeneity of gene editing in T cells, reducing costs and safety risks while enabling versatile modifications and enhancing therapeutic efficacy.
Smart Images

Figure 0007586549000001 
Figure 0007586549000002 
Figure 0007586549000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biotechnology, and in particular to a method for gene editing of a target site in a cell. [Background technology]
[0002] The CRISPR / Cas9 system is an adaptive immune mechanism derived from archaea and bacteria that resists the invasion of exogenous DNA fragments such as plasmids and phages. The system functions mainly through the gene locus that codes for the CRISPR sequence and the Cas protein, and currently, the most commonly used is the type II family of Cas9 nuclease, which functions only with a single effector protein. When exogenous DNA invades bacteria, the type II CRISPR system first integrates the invaded DNA between the CRISPR overlapping sequence. Then, CRISPR RNA (crRNA) containing the invaded DNA sequence is transcribed and processed. Then, transactivating CRISPR RNA (tracrRNA) binds to the crRNA and finally forms a complex with the Cas9 protein. Finally, the Cas9 protein functions as an endonuclease through its HNH and RuvC-like structural domains to induce DNA double-strand breaks. A double-strand break in DNA triggers the damage repair mechanism, and when a homologous template is present, precise homologous recombination repair occurs in cells to realize the insertion or replacement of exogenous sequences. So far, CRISPR / Cas9 technology has been successfully used in many fields and shows broad prospects. However, precise gene therapy using homologous recombination still faces many difficulties, and one of the main limiting factors is that the efficiency of homologous recombination is very low. Although many studies have reported various methods to increase the homologous recombination rate, more and more evidence shows that these methods are not applicable to all types of cells and their effects are not consistent. Therefore, finding a personalized approach to effectively enhance homologous recombination in specific cells is particularly important for cell type-based cell therapy.
[0003] Chimeric antigen receptor T-cell technology (CAR-T) is a novel adoptive immunotherapy that has emerged in recent years. It involves modifying the genes of a patient's T cells in vitro, and then reinjecting them into the patient's body after a certain degree of amplification to achieve targeted killing of tumors. Currently, three CAR-T products have been approved by the US Food and Drug Administration for the clinical treatment of hematological tumors, indicating the great success of CAR-T technology. However, as an emerging technology, CAR-T technology still faces many challenges in all aspects and has great room for improvement. First, the most commonly used method at present is to use the viral system to introduce exogenous sequences. However, the use of the viral system has problems such as high production costs and potential safety issues due to random insertion. Second, conventional technologies including viral production cannot realize the precise insertion of exogenous sequences into the genome, which reduces the uniformity of cells, affects the therapeutic effect, and makes it impossible to carry out further modifications on T cells. In addition, current CAR-T therapy is all individualized treatment, which has problems such as high production costs, long cycles, and limited efficacy. Therefore, using technologies such as CRISPR / Cas9 to site-specifically integrate artificially modified elements such as CARs into T cells is of great importance in promoting the development of existing T cell therapies. On the one hand, it can avoid the uncertainty caused by random insertion of exogenous sequences, and improve the uniformity and stability of cell products. On the other hand, it can realize diverse modifications of T cells, construct general CAR-T cells in one step, and not only can construct enhanced cell products by regulating endogenous genes, but also realize dynamic expression of artificial components, which is of great help in expanding the application of existing technologies. However, due to the particularity of the cell type of T cells themselves, the efficiency of site-specific integration of exogenous sequences by homologous recombination is always low. Therefore, it is urgent in the art to develop a method to improve the efficiency of homologous recombination in T cells. Summary of the Invention
[0004] One object of the present invention is to provide novel methods for improving the efficiency of homologous recombination of exogenous sequences in cells, particularly T cells.
[0005] The present invention provides gene editing methods for each of the AAVS1, PD1, TRAC, and B2M genes.
[0006] One aspect of the present invention provides a method for gene editing a target site in a cell genome, comprising the steps of: (a) providing a cell to be gene-edited; (b) (i) introducing a gene-editing enzyme or a nucleic acid encoding the gene-editing enzyme, or a first expression vector encoding the gene-editing enzyme; and (ii) introducing a gRNA or a second expression vector expressing the gRNA into the cell to gene-edit a target site in the cell genome, wherein the gRNA guides the gene-editing enzyme to specifically cleave the target site; Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0007] In another preferred embodiment, the gene editing includes gene knockout and gene targeted integration.
[0008] In another preferred embodiment, when the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 6, the gene editing is gene target integration.
[0009] In another preferred embodiment, when the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 7 to 9, the gene editing is a gene knockout.
[0010] In another preferred embodiment, the gene editing enzyme is selected from the group consisting of a CRISPR-associated protein (Cas) polypeptide, a TALEN enzyme, a ZFN enzyme, or a combination thereof.
[0011] In another preferred embodiment, the gene editing enzyme is of microbial origin, preferably of bacterial origin.
[0012] In another preferred embodiment, the gene editing enzyme is selected from the group consisting of Streptococcus pyogenes, Staphylococcus aureus, Streptococcus canis, or a combination thereof.
[0013] In another preferred embodiment, the gene editing enzyme includes a wild-type or mutant gene editing enzyme.
[0014] In another preferred embodiment, the gene editing enzyme is selected from the group consisting of Cas9, Cas12, Cas13, Cms1, MAD7, Cas3, Cas8a, Cas8b, Cas10d, Csel, Csy1, Csn2, Cas4, Cas10, Csm2, Cmr5, Fok1, Cpf1, or a combination thereof.
[0015] In another preferred embodiment, the gRNA comprises a crRNA, a tracrRNA, or a sgRNA.
[0016] In another preferred embodiment, the gRNA targets to a target site in the genome.
[0017] In another preferred embodiment, the gRNA includes unmodified and modified gRNA.
[0018] In another preferred embodiment, the modified gRNA comprises a chemical modification of the bases.
[0019] In another preferred embodiment, the chemical modification includes a methylation modification, a methoxy modification, a fluorination modification, or a thiol modification.
[0020] In another preferred embodiment, the gene editing includes in vivo gene editing and in vitro gene editing.
[0021] In another preferred embodiment, the gene editing comprises CRISPR-based gene editing.
[0022] In another preferred embodiment, the target site is selected from the group consisting of AAVS1, PD1, TRAC, B2M, or a combination thereof.
[0023] In another preferred embodiment, the target sequence of the gRNA targeting AAVS1 includes the sequence shown in SEQ ID NO:3.
[0024] In another preferred embodiment, the target sequence of the gRNA targeting PD1 comprises the sequence shown in SEQ ID NO:1 and / or SEQ ID NO:2.
[0025] In another preferred embodiment, the target sequence of the gRNA targeting TRAC includes the sequence shown in SEQ ID NO:4 and / or SEQ ID NO:5.
[0026] In another preferred embodiment, the target sequence of the gRNA targeting B2M includes the sequence shown in SEQ ID NO:6.
[0027] In another preferred embodiment, the gene editing includes site-specific knock-in into donor DNA.
[0028] In another preferred embodiment, the donor DNA is double-stranded DNA.
[0029] In another preferred embodiment, the donor DNA includes a first homology arm and a second homology arm, wherein the first homology arm and the second homology arm are capable of initiating cell-mediated homologous recombination of the donor DNA at a target site in the cell genome, and the sequence lengths of the first homology arm and the second homology arm are independently 200 to 2000 bp, preferably 400 to 1000 bp, and more preferably 700 to 900 bp.
[0030] In another preferred embodiment, the first homology arm is homologous to a sequence upstream (or to the left) of the cleavage site at the target site in the genome, and the second homology arm is homologous to a sequence downstream (or to the right) of the cleavage site at the target site in the genome.
[0031] In another preferred embodiment, the donor DNA further comprises a target gene.
[0032] In another preferred embodiment, the target gene comprises a coding sequence for a chimeric antigen receptor or TCR.
[0033] In another preferred embodiment, the sequence length of the donor DNA is 50 bp to 5000 bp, preferably 80 bp to 4000 bp.
[0034] In another preferred embodiment, the sequence length of the target gene is 50 bp to 3000 bp, preferably 1000 bp to 2000 bp.
[0035] In another preferred embodiment, the length of the coding sequence of the chimeric antigen receptor or TCR is 50 bp to 3000 bp, preferably 1000 bp to 2000 bp.
[0036] In another preferred embodiment, the ratio (D1 / D2) of the sequence length D1 of the first homology arm to the sequence length D2 of the second homology arm is (0.8-1.2):(0.5-1.5), preferably (0.9-1.1):(0.7-1.3), and more preferably 1:1.
[0037] In another preferred embodiment, the chimeric antigen receptor comprises an antigen-binding domain that targets a tumor cell marker.
[0038] In another preferred embodiment, the chimeric antigen receptor comprises an antigen-binding domain that targets a tumor cell marker, an optional hinge region, a transmembrane domain, and an intracellular signaling binding domain.
[0039] In another preferred embodiment, the tumor cell marker is alpha folate receptor, 5T4, alphavbeta6 integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD44, CD44v6, CD44v7 / 8, CD70, CD79a, CD79b, CD123, CD138, CD171, CEA, CSPG4, EGFR, EGFR family including ErbB2 (HER2), EGFRvIII, EGP2, EGP40, EPCAM, EphA2, EpCAM, FAP, fetal AchR, FRα, GD2, GD 3, glypican-3 (GPC3), HLA-A1+MAGE1, HLA-A2+MAGE1, HLA-A3+MAGE1, HLA-A1+NY-ESO-1, HLA-A2+NY-ESO-1, HLA-A3+NY-ESO-1, IL-11Rα, IL-13Rα2, Lambda, Lewis-Y, Kappa, mesothelin, Muc1, Muc16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSCA, PSMA, ROR1, SSX, survivin, TAG72, TEM, VEGFR2, WT-1, or a combination thereof.
[0040] In another preferred embodiment, the hinge region is a protein hinge region selected from the group consisting of CD8, an Ig (immunoglobulin) hinge, CD28, or a combination thereof.
[0041] In another preferred embodiment, the transmembrane domain is a protein transmembrane domain selected from the group consisting of CD8α, CD8β, CD28, CD33, CD37, CD5, CD16, ICOS, CD9, CD22, CD134, CD137, CD154, CD19, CD45, CD4, CD3ε, CD3γ, CD3ζ, or a combination thereof.
[0042] In another preferred embodiment, the intracellular signaling binding domain comprises a costimulatory signaling molecule and / or a primary signaling domain.
[0043] In another preferred embodiment, the costimulatory signaling molecule is selected from the group consisting of OX40, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), LIGHT, DAP10, CDS, ICAM-1, CD278 (ICOS), TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD54 (ICAM), CD83, LAT, NKD2C, SLP76, TRIM, ZAP70, or a combination thereof.
[0044] In another preferred embodiment, the primary signaling domain is selected from the group consisting of FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, CD66d, or a combination thereof.
[0045] In another preferred embodiment, the sequence of the donor DNA is as shown in any one of SEQ ID NOs: 12 to 38.
[0046] In another preferred embodiment, the cells include primary and passaged cells.
[0047] In another preferred embodiment, the cells include T cells.
[0048] In another preferred embodiment, the cells include CD3+ T cells, CD4+ helper T cells, CD4+ regulatory T cells, CD8+ T cells, and memory T cells.
[0049] In another preferred embodiment, the vector comprises a viral vector.
[0050] In another preferred embodiment, the viral vector is selected from the group consisting of an adeno-associated viral vector, a lentiviral vector, or a combination thereof.
[0051] In another preferred embodiment, the method of introduction includes electroporation, vector transformation, transfection, heat shock, electroporation, transduction, gene gun, microinjection, liposome transfection, lentiviral infection, and the like.
[0052] In another preferred embodiment, the method is an in vitro method.
[0053] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
[0054] A second aspect of the present invention provides a gRNA that genetically edits a target site in a cell genome, and the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0055] In another preferred embodiment, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 6.
[0056] In another preferred embodiment, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 7 to 9.
[0057] In another preferred embodiment, the gRNA includes unmodified and modified gRNA.
[0058] In another preferred embodiment, the modified gRNA comprises a chemical modification of the bases.
[0059] In another preferred embodiment, the chemical modification includes a methylation modification, a methoxy modification, a fluorination modification, or a thiol modification.
[0060] A third aspect of the present invention provides a reaction system for gene editing of a target site in a cell genome, the reaction system comprising: (a) Donor DNA, which is double-stranded DNA; (b) a gene-editing enzyme or a nucleic acid encoding same, or a first expression vector expressing the gene-editing enzyme; (c) a gRNA or a second expression vector expressing the gRNA; Includes:
[0061] Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0062] In another preferred embodiment, the gene editing includes gene knockout and gene targeted integration.
[0063] In another preferred embodiment, when the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 6, the gene editing is gene target integration.
[0064] In another preferred embodiment, when the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 7 to 9, the gene editing is a gene knockout.
[0065] In another preferred embodiment, the target site is selected from the group consisting of AAVS1, PD1, TRAC, B2M, or a combination thereof.
[0066] In another preferred embodiment, the target sequence of the gRNA targeting AAVS1 includes the sequence shown in SEQ ID NO:3.
[0067] In another preferred embodiment, the target sequence of the gRNA targeting PD1 comprises the sequence shown in SEQ ID NO:1 and / or SEQ ID NO:2.
[0068] In another preferred embodiment, the target sequence of the gRNA targeting TRAC includes the sequence shown in SEQ ID NO:4 and / or SEQ ID NO:5.
[0069] In another preferred embodiment, the target sequence of the gRNA targeting B2M includes the sequence shown in SEQ ID NO:6.
[0070] In another preferred embodiment, the donor DNA includes a first homology arm and a second homology arm, wherein the first homology arm and the second homology arm can initiate cell-mediated homologous recombination of the donor DNA at a target site in a cell genome, and the sequence lengths of the first homology arm and the second homology arm are independently 200 to 2000 bp, preferably 400 to 1000 bp, and more preferably 700 to 900 bp.
[0071] In another preferred embodiment, the donor DNA further comprises a target gene.
[0072] In another preferred embodiment, the target gene comprises a coding sequence for a chimeric antigen receptor or TCR.
[0073] In another preferred embodiment, the chimeric antigen receptor comprises an antigen-binding domain that targets a tumor cell marker.
[0074] In another preferred embodiment, the chimeric antigen receptor comprises an antigen-binding domain that targets a tumor cell marker, an optional hinge region, a transmembrane domain, and an intracellular signaling binding domain.
[0075] In another preferred embodiment, the tumor cell marker is alpha folate receptor, 5T4, alphavbeta6 integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD44, CD44v6, CD44v7 / 8, CD70, CD79a, CD79b, CD123, CD138, CD171, CEA, CSPG4, EGFR, EGFR family including ErbB2 (HER2), EGFRvIII, EGP2, EGP40, EPCAM, EphA2, EpCAM, FAP, fetal AchR, FRα, GD2, GD 3, glypican-3 (GPC3), HLA-A1+MAGE1, HLA-A2+MAGE1, HLA-A3+MAGE1, HLA-A1+NY-ESO-1, HLA-A2+NY-ESO-1, HLA-A3+NY-ESO-1, IL-11Rα, IL-13Rα2, Lambda, Lewis-Y, Kappa, mesothelin, Muc1, Muc16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSCA, PSMA, ROR1, SSX, survivin, TAG72, TEM, VEGFR2, WT-1, or a combination thereof.
[0076] In another preferred embodiment, the hinge region is a protein hinge region selected from the group consisting of CD8, an Ig (immunoglobulin) hinge, CD28, or a combination thereof.
[0077] In another preferred embodiment, the transmembrane structural domain is a protein transmembrane domain selected from the group consisting of CD8α, CD8β, CD28, CD33, CD37, CD5, CD16, ICOS, CD9, CD22, CD134, CD137, CD154, CD19, CD45, CD4, CD3ε, CD3γ, CD3ζ, or a combination thereof.
[0078] In another preferred embodiment, the intracellular signaling binding domain comprises a costimulatory signaling molecule and / or a primary signaling structural domain.
[0079] In another preferred embodiment, the costimulatory signaling molecule is selected from the group consisting of OX40, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), LIGHT, DAP10, CDS, ICAM-1, CD278 (ICOS), TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD54 (ICAM), CD83, LAT, NKD2C, SLP76, TRIM, ZAP70, or a combination thereof.
[0080] In another preferred embodiment, the primary signaling structural domain is selected from the group consisting of FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, CD66d, or a combination thereof.
[0081] In another preferred embodiment, the cells include primary and passaged cells.
[0082] In another preferred embodiment, the cells include T cells.
[0083] In another preferred embodiment, the cells include CD3+ T cells, CD4+ helper T cells, CD4+ regulatory T cells, CD8+ T cells, and memory T cells.
[0084] In another preferred embodiment, the first homology arm is homologous to a sequence upstream (or to the left) of the cleavage site at the target site in the genome, and the second homology arm is homologous to a sequence downstream (or to the right) of the cleavage site at the target site in the genome.
[0085] In another preferred embodiment, the sequence length of the donor DNA is 50 bp to 5000 bp, preferably 80 bp to 4000 bp.
[0086] In another preferred embodiment, the sequence length of the target gene is 50 bp to 3000 bp, preferably 1000 bp to 2000 bp.
[0087] In another preferred embodiment, the length of the coding sequence of the chimeric antigen receptor or TCR is 50 bp to 3000 bp, preferably 1000 bp to 2000 bp.
[0088] In another preferred embodiment, the sequence of the donor DNA is as shown in any one of SEQ ID NOs: 12 to 38.
[0089] In another preferred embodiment, the vector comprises a viral vector.
[0090] In another preferred embodiment, the viral vector is selected from the group consisting of an adeno-associated viral vector, a lentiviral vector, or a combination thereof.
[0091] A fourth aspect of the present invention provides a gene editing kit, the kit including: i) a first container and a donor DNA, the donor DNA being double-stranded DNA located within the first container; ii) a second container and a gene editing enzyme or a nucleic acid encoding the gene editing enzyme located in the second container, or a first expression vector expressing the gene editing enzyme; and iii) a third container and a gRNA or a second expression vector expressing the gRNA located in the third container; Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0092] In another preferred embodiment, the first container, the second container and the third container are the same container or are different containers.
[0093] A fifth aspect of the present invention provides a gene-edited cell produced by a method according to the first aspect of the present invention.
[0094] A sixth aspect of the invention provides the use of a cell according to the method according to the fifth aspect of the invention in the manufacture of a tumour immunotherapy or cancer immunotherapy product.
[0095] It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features (such as embodiments) specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here due to space limitations. [Brief description of the drawings]
[0096] In the figures of the present application, "Untreated T" indicates untreated T cells, "Control" indicates T cells electroporated with only the homologous template and Cas9, "LV-19bbz" indicates lentivirally produced CD19-CART cells, "AAVS1-19bbz" indicates non-viral AAVS1 site-specifically integrated CD19-CART cells, and "PD1-19bbz" indicates non-viral PD1 site-specifically integrated CD19-CART cells. [Figure 1] Schematic diagram of the construction principle of non-viral site-specific integrated CAR-T cells. "TRAC-19bbz" represents non-viral TRAC site-specific integrated CD19-CART cells, and "B2M-19bbz" represents non-viral B2M site-specific integrated CD19-CART cells. [Diagram 2] Figure 2 shows T cell viability after electroporation of plasmid or linear double-stranded DNA. In the control group, only plasmid or linear double-stranded DNA is electroporated, and in the sample group, template, Cas9 and sgRNA are electroporated simultaneously. [Diagram 3] mTurquoise2 positivity rate after electroporation using different templates. The control group was electroporated with HDR template and Cas9 only, the sample group was electroporated with linear double-stranded DNA template, Cas9 and sgRNA, and pb indicates the addition of protective bases on both sides. [Figure 4] The mTurquoise2 positive rate and cell viability after electroporation of templates with different homology arm lengths are shown. The control group is electroporation of 800bp homology template and Cas9 only, and the sample group is electroporation of different homology arm templates, Cas9 and sgRNA; Panel A is the positive rate of mTurquoise2, Panel B is the relative number of live cells, and Panel C is the relative number of mTurquoise2 positive live cells. [Diagram 5] AAVS1 site sgRNA screening. Figure A shows the knockout rate of the AAVS1 site detected by T7E1, and Figure B shows the recombination rate of the fluorescent protein mTurquioise2 sequence at the AAVS1 site. In the figure, "sgRNA-1" represents the AAVS1-sgRNA1 of the present application, "sgRNA-2" represents the AAVS1-sgRNA2 of the present application, "sgRNA-3" represents the AAVS1-sgRNA3 of the present application, and "sgRNA-4" represents the AAVS1-sgRNA3 of the present application. [Figure 6] The figure shows the screening of sgRNA at the PD1 site, which is the recombination rate of the fluorescent protein mTurquioise2 sequence at the PD1 site. In the figure, "sgRNA-1" refers to the PD1-sgRNA1 of the present application, and "sgRNA-2" refers to the PD1-sgRNA2 of the present application. [Figure 7]sgRNA screening at the TRAC site. Figure A shows the knockout rate of the TRAC site detected by CD3 expression, and Figure B shows the recombination rate of the fluorescent protein mTurquioise2 sequence at the TRAC site. In the figure, "sgRNA-1" indicates the TRAC-sgRNA1 of the present application, "sgRNA-2" indicates the TRAC-sgRNA2 of the present application, and "sgRNA-3" indicates the TRAC-sgRNA3 of the present application. [Figure 8] sgRNA screening at the B2M site. Figure A shows the knockout rate of the B2M site detected by B2M expression, and Figure B shows the recombination rate of the fluorescent protein mTurquioise2 sequence at the B2M site. In the figure, "sgRNA-1" indicates the B2M-sgRNA1 of the present application, and "sgRNA-2" indicates the B2M-sgRNA2 of the present application. [Figure 9] CAR positive rate and cell viability after electroporation of different length homology arm templates. The control group is electroporation of 800bp homology template and Cas9 only, and the sample group is electroporation of different length homology arm templates, Cas9 and sgRNA; Figure A is the CAR positive rate, Figure B is the relative number of live cells, and Figure C is the relative number of CAR positive live cells. [Figure 10] The positive rates of CD19-CART cells with AAVS1 site-specific integration in CD3+, CD4+, and CD8+ T cells are shown. [Figure 11] Positivity and knockout rates of CD19-dCART cells with AAVS1 site-specific integration. Figure A shows the positivity and knockout rates of CD19-CART cells with AAVS1 site-specific integration prepared from different human donor cells; Figure B shows the positivity and knockout rates of AAVS1 site-specific integrated CD19-CART cells prepared from five representative different human donor cells; Figure C shows the positivity of AAVS1 site-specific integrated CD19-CART cells by flow cytometry analysis. The control group is electroporation of homologous template and Cas9 only. [Figure 12]DNA sequencing of CD19-CART cells with AAVS1 site-specific integration. HA indicates the homology arm. [Figure 13] T cell viability of AAVS1 site-specific integration is shown. [Figure 14] 1 shows in vitro expansion of AAVS1 site-specific integrated T cells. [Figure 15] 1 shows in vitro expansion of AAVS1 site-specific integration by co-culture of CD19-CART cells and target cells. [Figure 16] In vitro expansion of CD19-CART cells and target cells co-cultured with AAVS1 site-specific integration detected by labeling, as controlled by electroporation of homologous template and Cas9 alone. [Figure 17] The expression of CD19-CART cell surface markers upon AAVS1 site-specific integration is shown. Controls are homology template and Cas9-only electroporation. [Figure 18] The percentage of CD19-CART cell subtypes with AAVS1 site-specific integration is shown, as control group is electroporation with homology template and Cas9 only. [Figure 19] Detection of CD19-CART cell secreted factors following AAVS1 site-specific integration. Control group is electroporation with homology template and Cas9 only. [Figure 20] In vitro killing of CD19-CART cells with AAVS1 site-specific integration, control group is electroporation of homology template and Cas9 only. [Figure 21] 1 shows in vivo killing of AAVS1 site-specifically integrated CD19-CART cells. The tumor target cells are Raji cells. [Figure 22]The positive rate and knockout rate of CD19-CART cells with PD1 site-specific integration are shown. Figure A shows the positive rate of CD19-CART cells with PD1 site-specific integration prepared from different human donor cells, and Figure B shows the positive rate and knockout rate of CD19-CART cells with PD1 site-specific integration prepared from five representative different human donor cells; Figure C shows the positive rate of CD19-CART cells with PD1 site-specific integration by flow cytometry analysis; Figure D shows a comparison of PD1 expression between CD19-CART cells with PD1 site-specific integration and CD19-CART cells prepared with lentivirus. The control group is electroporation of homologous template and Cas9 only. [Figure 23] DNA sequencing of CD19-CART cells with PD1 site-specific integration. HA is the homology arm. [Figure 24] 1 shows in vitro expansion of PD1 site-specific integrated CD19-CART cells co-cultured with target cells. [Diagram 25] Expression of CD19-CART cell surface markers of PD1 site-specific integration is shown. Control group is electroporation with homology template and Cas9 only. [Figure 26] Detection of CD19-CART cell secreted factors upon PD1 site-specific integration. Control group is electroporation of homology template and Cas9 only. [Figure 27] In vitro killing of CD19-CART cells with PD1 site-specific integration. Control group is electroporation of homology template and Cas9 only. [Figure 28] 1 shows in vivo killing of PD1 site-specific integrated CD19-CART cells. The tumor target cells are Raji cells that overexpress PDL1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0097] After extensive and thorough research, through multiple screenings, the inventors unexpectedly screened for gRNAs that can efficiently edit target sites (e.g., AAVS1, PD1, TRAC, B2M). Furthermore, by comparing different lengths of the first and second homology arms, the inventors were also able to confirm the conditions for efficient integration of exogenous nucleic acid into the genome of T cells (e.g., conditions under which the first and second homology arms of a specific length can efficiently integrate into the genome target site). The present invention was completed based on this.
[0098] (term) CRISPR / Cas9-mediated gene editing CRISPR / Cas9 is an adaptive immune defense that has formed over the long-term evolutionary course of bacteria and archaea and can be used to fight invading viruses and exogenous DNA. The CRISPR / Cas9 system provides immunity by integrating fragments of invading phage and plasmid DNA into CRISPR and inducing the degradation of homologous sequences using the corresponding CRISPR RNA (e.g., gRNA).
[0099] The working principle of the system is that crRNA (CRISPR-derived RNA) binds to tracrRNA (trans-activating RNA) through base pairing to form a tracrRNA / crRNA complex, which guides the nuclease Cas9 protein to cleave double-stranded DNA at the sequence target site paired with the crRNA. By artificially designing these two RNAs, a gRNA (single guide RNA) with sufficient guide function to guide Cas9 to cleave DNA at a specific site can be designed.
[0100] As an RNA-guided dsDNA binding protein, Cas9 effector nuclease is the first known unifying factor, which can localize RNA, DNA and proteins together. By fusing the protein with nuclease-free Cas9 (nuclease-null Cas9) and expressing the appropriate gRNA, any dsDNA sequence can be targeted, and the end of the gRNA can connect to the target DNA without affecting the binding of Cas9. Thus, Cas9 can bring about any fusion protein and RNA at any dsDNA sequence. Such a technology is called the CRISPR / Cas9 gene editing system.
[0101] Target Integration Mechanism In the targeted integration strategy of the present invention, a linearized donor (i.e., donor DNA or exogenous nucleic acid) containing a homology arm of a specific length is provided, such a donor is a transgenic donor of a homology arm containing a specific length (e.g., 700-900 bp) obtained by PCR amplification or precise enzymatic digestion; the donor DNA or exogenous nucleic acid is electrotransferred into cells together with Cas9 mRNA and guide RNA. Compared with existing gene targeting strategies, the targeted integration strategy provided by the present invention has a higher integration efficiency.
[0102] In the present invention, a linearized dsDNA donor (i.e., donor DNA or exogenous nucleic acid) consisting of a transgene fragment and 700-900 bp homology arms on both sides is the key to achieving efficient targeted integration in CRISPR-mediated genome editing. Compared with the methods mediated by MMEJ (microhomology arm-mediated end joining) or HITI (non-homologous sequence end joining), the targeted integration technique of the present invention has the highest recombination rate.
[0103] Method for gene editing at a target site in a cell genome The present invention provides a method for gene editing a target site in a cell genome, comprising the steps of: (a) providing a cell to be gene-edited; (b) (i) a gene-editing enzyme or a nucleic acid encoding the gene-editing enzyme, or a first expression vector encoding the gene-editing enzyme; and (ii) a gRNA or a second expression vector expressing the gRNA is introduced into the cell to gene-edit a target site in the cell genome, and the gRNA guides the gene-editing enzyme to specifically cleave the target site; Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0104] The methods of the present invention can perform highly efficient gene knockout or gene targeted integration at target sites (e.g., AAVS1, PD1, TRAC, B2M, etc.).
[0105] Reaction system The present invention provides a reaction system for gene editing of a target site in a cell's genome, comprising: (a) Donor DNA, which is double-stranded DNA; (b) a gene-editing enzyme or a nucleic acid encoding same, or a first expression vector expressing the gene-editing enzyme; (c) a gRNA or a second expression vector expressing the gRNA; Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 9.
[0106] In one preferred embodiment, the donor DNA includes a first homology arm and a second homology arm, wherein the first homology arm and the second homology arm are capable of initiating immune cell-mediated homologous recombination of the donor DNA at a target site in the immune cell genome, and the sequence length of the first homology arm and the second homology arm are independently 200 to 2000 bp, preferably 400 to 1000 bp, and more preferably 700 to 900 bp.
[0107] In the present invention, the sequence length of the donor DNA to be integrated may be 50 bp to 5000 bp. The length of the target gene (or referred to as the target gene) in the donor DNA of the present invention may be 50 bp to 3000 bp.
[0108] In the present invention, the target site is not particularly limited, but preferred target sites include AAVS1, PD1, TRAC, and B2M.
[0109] In a preferred embodiment of the present invention, the ratio (D1 / D2) of the sequence length D1 of the first homology arm to the sequence length D2 of the second homology arm is (0.8 to 1.2):(0.5 to 1.5), preferably (0.9 to 1.1):(0.7 to 1.3), and more preferably 1:1.
[0110] In the reaction system of the present invention, the sequence lengths of the two homologous arms do not need to be completely identical, and a certain degree of difference in length between them is permissible.
[0111] The main advantages of the present invention include: 1) The gene editing (e.g., site-specific integration) efficiency of the method of the present invention is significantly higher than other existing gene editing techniques. 2) The introduction method is simple and can be achieved by methods such as electroporation. 3) The present invention can improve the efficiency of site-specific integration of exogenous nucleic acids in T cells. 4) Using the methods of the present invention, it is possible to prepare site-specific integrated T cell products. 5) The method of the present invention can prepare non-viral site-specific integrated CAR-T cells at sites such as AAVS1, PD1, TRAC, B2M, etc., avoiding many of the shortcomings of viral preparation and improving the uniformity and stability of CAR-T products. In addition, it provides technical support for the preparation of enhanced, inducible, and other CAR-T products.
[0112] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Experimental methods for which no specific conditions are shown in the following examples generally follow conventional conditions such as those described in Molecular Cloning: A Laboratory Handbook by Sambrook et al. (New York: Cold Spring Harbor Laboratory Press, 1989), or those described in Microorganisms: A Laboratory Manual (James Cappuccino and Natalie Sherman, eds., Pearson Education Publishers), or manufacturer's suggested conditions. All human donor cells used in the experiments related to this patent were obtained from Shanghai Saili Biotechnology Co., Ltd.
[0113] Unless otherwise stated, materials and reagents used in the examples are commercially available.
[0114] Normal Method Electroporation of IT cells T cell electroporation is a technical method to achieve gene editing of T cells, and the procedure is based on Lonza's P3 Primary Cell 4D-Nucleofector® X kit.
[0115] Equipment and materials: (i) Lonza 4D-Nucleofector® System nuclear transfer device (ii) The kit is P3 Primary Cell 4D-Nucleofector® TMX Kit (Lonza, V4XP-3024). (iii) T cells 2–4 days after CD3 / CD28 magnetic bead stimulation (iv) Commercially available spCas9 protein (5ug / ul) (TrueCut® Cas9 Protein v2, Thermofisher) (v) Synthesized sgRNA (dissolve the synthesized sgRNA in TE buffer and dilute it to a final concentration of 10ug / uL) (vi) Linearized double-stranded DNA containing the homologous template
[0116] Specific operation steps: Suitable for 100 μl electroporation cups. (1) Prepare the electroporation solution mixture according to the total number of electroporations: 82 μl of Solution + 18 μl of supplements / each electroporation cup, mix evenly, and leave at room temperature. (2) Cas9 protein and sgRNA9 are co-incubated at room temperature for 10 minutes to allow RNP formation. (3) Linearized homology template double-stranded DNA (containing the fluorescent protein mTurquoise2 sequence with homology arms to two sites of PD1, and the CD19-CART sequence with homology arms to AAVS1, PD1, TRAC, and B2M) is added to the RNP and incubated at room temperature for 2 minutes. The CD19-CART comprises an extracellular structural domain that targets CD19, a transmembrane domain selected from CD8α, and an intracellular signaling structural domain selected from CD3ζ and CD137. (4) Activated T cells were collected and diluted to 5 × 10 6 Count until completion of the electroporation reaction. (5) Thoroughly mix and resuspend the cells and “RNP + homology template” and add to the electroporation cup. (6) Turn on the electroporation device, place the electroporation cup into the slot, and select the corresponding program EO115 to perform electroporation. (7) Add the cells to the pre-warmed cell culture medium and culture them in a cell culture incubator.
[0117] II. Detection of exogenous sequence recombination rates 1) Place 1 x 10 cells in a sterile 1.5 ml centrifuge tube. 6Take the cells, centrifuge them and discard the supernatant. 2) Add flow buffer (PBS containing 2% serum) to the cell pellet to wash the cells. 3) Place in a centrifuge at room temperature and, after centrifugation, aspirate off as much of the supernatant as possible. 4) Co-incubate with detection antibody or protein and incubate on ice for 30 minutes. 5) Wash the cells twice with flow buffer, centrifuge, and then aspirate off as much of the supernatant as possible. 6) Resuspend the cells in an appropriate volume of flow buffer and perform streaming analysis on the instrument.
[0118] III. Detection of viable cell count The number of viable cells was detected using Promega's Celltiter One Solution Cell Proliferation Assay kit, and the operating procedure was described in the manufacturer's instructions. 1) Equilibrate the MTS reagent to room temperature. 2) Set up three replicate wells, take 100 μl of cell suspension into a 96-well plate and add 20 μl of MTS reagent. 3) Incubate in a 37℃ incubator containing 5% CO2 for 4 hours. 4) Detect using a microplate reader at 490 nm and perform statistics and analysis of the data.
[0119] For example, the method of the present invention can be used in combination with CRISPR / Cas9 technology to construct CD19-CART cells with non-viral site-specific integration (including CAR-T cells with AAVS1 safety site integration, CD19-CART cells with immune checkpoint PD1 site integration, CD19-CART cells with TRAC site integration, and CD19-CART cells with B2M site integration) in a single step.
[0120] 1. Target sequence information: AAVS1-sgRNA1: CCGGAGAGGACCCAGACACG (SEQ ID NO: 7) AAVS1-sgRNA2: AGAGCTAGCACAGACTAGAG (SEQ ID NO: 3) AAVS1-sgRNA3: AAAGCAAGAGGATGGAGAGG (SEQ ID NO: 8) AAVS1-sgRNA4: GAGAGGACCCAGACACGGGG (SEQ ID NO: 9) PD1-sgRNA1: CGACTGGCCAGGGCGCCTGT (SEQ ID NO: 1) PD1-sgRNA2: GGCGGGTGCTACAACTGGGC (SEQ ID NO: 2) TRAC-sgRNA1: ACAAAACTGTGCTAGACATG (SEQ ID NO: 4) TRAC-sgRNA2: AGAGCAACAGTGCTGTGGCC (SEQ ID NO: 5) TRAC-sgRNA3: AGAGTCTCTCAGCTGGTACA (SEQ ID NO: 10) B2M-sgRNA1: ACTCACGCTGGATAGCCTCC (SEQ ID NO: 11) B2M-sgRNA2: GAGTAGCGCGAGCACAGCTA (SEQ ID NO: 6) 2. sgRNA is synthesized by the company, dissolved in TE buffer, and diluted to a final concentration of 10ug / uL. 3. Preparation of non-viral site-specific integration of CD19-CART by electroporation.
[0121] Equipment and Materials: (i) Lonza 4D-Nucleofector® System nuclear transfer device (ii) The kit is P3 Primary Cell 4D-Nucleofector® X Kit (Lonza, V4XP-3024). (iii) T cells 2–3 days after CD3 / CD28 magnetic bead stimulation (iv) Commercially available spCas9 protein (5ug / ul) (TrueCut® Cas9 Protein v2, Thermofisher) (v) sgRNA synthesized in-house (vi) a linearized double-stranded D sequence containing the homology template;
[0122] Specific operation steps: Suitable for 100 μl electroporation cups. (1) Prepare the electroporation solution mixture according to the total number of electroporations: 82 μl of Solution + 18 μl of supplement / each electroporation cup, mix evenly, and leave at room temperature. (2) Cas9 protein is co-incubated with AAVS1-sgRNA, PD1-sgRNA1, PD1-sgRNA2, TRAC-sgRNA, and B2M-sgRNA, respectively, and left at room temperature for 10 minutes to form RNPs. (3) Linearized double-stranded DNA containing homology arms at each site is added to the RNP and incubated at room temperature for 2 min. (4) Collect activated T cells and measure 5 × 10 6 Count until completion of the electroporation reaction. (5) Thoroughly mix and resuspend the cells and “RNP + homologous template” and add to the electroporation cup. (6) Turn on the electroporation device, place the electroporation cup into the slot, and select the corresponding program EO115 to perform electroporation. (7) Place the cells in pre-warmed cell culture medium and culture them in a cell incubator.
[0123] 4. Assessing AAVS1 site-specific integration in CD19-CART cells (1) Using the present invention, CAR-T cells with AAVS1 site-specific integration can be constructed without the use of viruses, with a CAR positivity rate of approximately 10%-20% (Figure 11) and a knockout rate of approximately 65%-90% (Figure 11), and the method can achieve site-specific integration of CAR elements in any of CD3+, CD4+, and CD8+ T cells (Figure 10). (2) The use of AAVS1 site-specifically integrated CD19-CART cells constructed according to the present invention has a relatively high survival rate (Figure 13). Although the electroporation step itself causes some cell death, it does not affect the effective proliferation of AAVS1 site-specifically integrated CD19-CART cells (Figures 14-16). (3) Although there were some differences between CD19-CART cells with AAVS1 site-specific integration and CD19-CART cells prepared with lentivirus, overall they showed similar characteristics in terms of cell surface marker expression, changes in cell subtypes, and cytokine secretion (Figures 17-19). (4) Similar to lentivirus-prepared CD19-CART cells, the AAVS1 site-specifically integrated CD19-CART cells constructed according to the present invention can effectively kill tumor cells both in vitro and in vivo (Figures 20 and 21).
[0124] 5. Evaluate PD1 site-specific integration on CD19-CART cells (1) By using the present invention, PD1 site-specific integrated CAR-T cells can be constructed without using viruses, and the CAR positivity rate is about 10% to 30% (Figure 22), and the knockout rate is about 80% to 95% (Figure 22). (2) The CD19-CART cells with PD1 site-specific integration constructed by the present invention have stronger proliferation ability than CD19-CART cells prepared by lentivirus (Figure 24). (3) Similar to the CD19-CART cells prepared by lentivirus, the CD19-CART cells with PD1 site-specific integration can activate the expression of surface markers in response to tumor cell stimulation, among which the increase in the expression level of CD137 is more significant (Figure 25). (4) Similar to the CD19-CART cells prepared by lentivirus, the CD19-CART cells with PD1 site-specific integration can secrete cytokines in response to tumor cell stimulation, among which the increase in IFN-γ secretion level is more significant (Figure 26). (5) Compared with lentivirus-prepared CD19-CART cells, the PD1 site-specific integrated CD19-CART cells constructed using the present invention show superior tumoricidal activity both in vivo and in vitro (Figures 27 and 28).
[0125] In the present application, the experiments are carried out using the following linear double-stranded DNA (donor DNA) as an example.
[0126] Here, the plasmid sequence is explained as follows. (1) The situation of vector and donor DNA is described using the 800 bp DNA plasmid donor sequence of the mTurquoise2 homology arm for PD1 site 1 specific integration as an example. The vector has a circular structure and the backbone of the vector is from the plasmid pmaxGFP® purchased from Lonza. The donor DNA sequence is the same as the "800bp DNA donor sequence of the homology arm of mTurquoise2 for PD1 site 1 specific integration (HDR)" in the linear double-stranded DNA sequence, i.e., as shown in SEQ ID NO:12.
[0127] (2) The situation of the vector and donor DNA is illustrated by taking the 800 bp DNA plasmid donor sequence of the mTurquoise2 homology arm for PD1 site 1 specific integration as an example. The vector has a circular structure and the backbone of the vector is from the plasmid pmaxGFP® purchased from Lonza. The donor DNA sequence is the same as the linear double-stranded DNA sequence "800 bp DNA donor sequence of the homology arm of mTurquoise2 for PD1 site 2-specific integration (HDR)", i.e., as shown in SEQ ID NO:13.
[0128] The linear double-stranded DNA (donor DNA) is as shown in any one of SEQ ID NOs:12 to 38.
[0129] wherein the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 1 specific integration is as shown in SEQ ID NO: 12, the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 2 specific integration is as shown in SEQ ID NO: 13, the 200bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 1 specific integration is as shown in SEQ ID NO: 14, and the 200bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 1 specific integration is as shown in SEQ ID NO: 15. The 400bp DNA donor sequence (HDR) is as shown in SEQ ID NO: 15, the 1600bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 1 specific integration is as shown in SEQ ID NO: 16, the 200bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 2 specific integration is as shown in SEQ ID NO: 17, the 400bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of PD1 site 2 specific integration is as shown in SEQ ID NO: 18, The 1600bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 for AAVS1 site 2 specific integration is as shown in SEQ ID NO: 19, the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 for AAVS1 site 1 / 4 specific integration is as shown in SEQ ID NO: 20, the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 for AAVS1 site 2 specific integration is as shown in SEQ ID NO: 21, and the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 for AAVS1 site 3 specific integration is as shown in SEQ ID NO: 22. The 800bp DNA donor sequence (HDR) is as shown in SEQ ID NO: 22, the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of TRAC site 1 specific integration is as shown in SEQ ID NO: 23, the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of TRAC site 2 specific integration is as shown in SEQ ID NO: 24, and the 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 of TRAC site 3 specific integration is as shown in SEQ ID NO: 25,The 800bp DNA donor sequence (HDR) of the homology arm of mTurquoise2 for B2M site 2 specific integration is as shown in SEQ ID NO: 26, the 200bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for AAVS1 site 2 specific integration is as shown in SEQ ID NO: 27, and the 400bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for AAVS1 site 2 specific integration is as shown in SEQ ID NO: 28, The 800 bp DNA donor sequence (HDR) of the homology arm of the CD19-CAR of the integration is as shown in SEQ ID NO: 29, the 200 bp DNA donor sequence (HDR) of the homology arm of the CD19-CAR of the PD1 site 1 specific integration is as shown in SEQ ID NO: 30, the 400 bp DNA donor sequence (HDR) of the homology arm of the CD19-CAR of the PD1 site 1 specific integration is as shown in SEQ ID NO: 31, The 800 bp DNA donor sequence (HDR) is as shown in SEQ ID NO: 32, the 200 bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for TRAC site 2 specific integration is as shown in SEQ ID NO: 33, the 400 bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for TRAC site 2 specific integration is as shown in SEQ ID NO: 34, and the 800 bp DNA donor sequence (HD R) is as set forth in SEQ ID NO: 35, the 200 bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for B2M site 2 specific integration is as set forth in SEQ ID NO: 36, the 400 bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for B2M site 2 specific integration is as set forth in SEQ ID NO: 37, and the 800 bp DNA donor sequence (HDR) of the homology arm of CD19-CAR for B2M site 2 specific integration is as set forth in SEQ ID NO: 38.
[0130] The sequence of the linear double-stranded DNA (donor DNA) as a comparative example is as shown in any one of SEQ ID NOs:39 to 44.
[0131] Here, the 800bp DNA donor sequence of the mTurquoise2 homology arm of PD1 site 1 specific integration (HITI-pb or "HITI(pb)") is as shown in SEQ ID NO: 39, the 800bp DNA donor sequence of the mTurquoise2 homology arm of PD1 site 1 specific integration (HITI) is as shown in SEQ ID NO: 40, and the 800bp DNA donor sequence of the mTurquoise2 homology arm of PD1 site 1 specific integration (MMEJ) is as shown in SEQ ID NO: 41. The 800 bp DNA donor sequence of the homology arm of mTurquoise2 for PD1 site 2-specific integration (HITI-pb or "HITI(pb)") is as shown in SEQ ID NO: 42, the 800 bp DNA donor sequence of the homology arm of mTurquoise2 for PD1 site 2-specific integration (HITI) is as shown in SEQ ID NO: 43, and the 800 bp DNA donor sequence of the homology arm of mTurquoise2 for PD1 site 2-specific integration (MMEJ) is as shown in SEQ ID NO: 44.
[0132] In the figures of the present application, "Untreated T" indicates untreated T cells, "Control" indicates T cells electroporated with only homologous template and Cas9, "LV-19bbz" indicates lentivirally produced CD19-CART cells, "AAVS1-19bbz" indicates CD19-CART cells with non-viral AAVS1 site-specific integration, and "PD1-19bbz" indicates CD19-CART cells with non-viral PD1 site-specific integration.
[0133] Example 1 The method of using linear double-stranded DNA as a homology template is superior to plasmids. When the length of the homology arms of the homology template is set to 800 bp, it has the highest recombination rate and can obtain the most positive cells, which is the optimal condition.
[0134] First, the effects of delivering templates in the form of plasmid and linear double-stranded DNA on T cells were compared. The results showed that when the templates were delivered in the form of linear double-stranded DNA, the cell viability was significantly higher than that of plasmid (Figure 2). Next, the effects of different template designs on the recombination rate were compared, among which HDR is a template containing 800bp homology arms, MMEJ is a template containing 20bp micro-homology arms, HITI is a template containing sgRNA targets on both sides but without homology arms, HITI(pb) is a template based on HITI with 50bp protective bases added to both ends, the donor sequences of HITI, HITI(pb), and MMEJ at PD1 site 1 were as shown in SEQ ID NOs: 39-41, respectively, and the donor sequences of HITI, HITI(pb), and MMEJ at PD1 site 2 were as shown in SEQ ID NOs: 42-44, respectively. As a result, it was found that the HDR template had the highest recombination rate (Figure 3). Based on the above results, we found that using linear double-stranded DNA containing homology arms as a template to construct CAR-T cells with non-viral site-specific integration was the optimal method (Figure 1).
[0135] We then compared the effect of the length of the homology arm. First, we used the fluorescent protein mTurquoise2 sequence as the exogenous sequence and performed recombination experiments at two PD1 sites (Figure 4). As a result, when the homology arm length was 200bp, 400bp, 800bp, and 1600bp, all showed good integration effects, and the integration rate of mTurquoise2 increased as the length of the homology arm increased, but 1600bp did not show a significant increase in integration rate compared to 800bp. Meanwhile, the cell viability showed a significant negative relationship with the length of the homology arm. Taking into account the recombination rate and cell viability, we analyzed the number of mTurquoise2-positive viable cells. The results showed that the most positive cells were obtained when the homology arm length was 800bp. Based on this, we performed validation again for the high-efficiency integration site of PD1, and performed screening for the high-efficiency integration sites of AAVS1, TRAC, and B2M. By comparing the knockout rate and mTurquoise2 recombination rate, we finally determined that PD1-sgRNA1, AAVS1-sgRNA2, TRAC-sgRNA2, and B2M-sgRNA2 were the preferred sequences (Figures 5-8). Finally, we used the CAR element as the exogenous sequence to construct CD19-CART cells with AAVS1, PD1, TRAC, and B2M site-specific integration, respectively, and compared the effects of different lengths of homology arms. Consistent with the results of mTurquoise2 recombination, the maximum number of positive cells could be prepared when the homology arm was 800 bp (Figure 9). Therefore, we confirmed that the HDR template containing 800 bp homology arms was the optimal condition for constructing T cells with site-specific integration.
[0136] In the previous experiment, the main + The conditions for site-specific integration of T cells were investigated and optimized. Based on this, the same method was used to + and CD8 + We attempted to edit T cells. The results showed that this method can + , CD4 + , and CD8 + We showed that T cells had similar site-specific integration rates (Figure 10).
[0137] Example 2 Using the method of the present invention, construct CD19-CART cells with non-viral AAVS1 site-specific integration and detect their function Using the method of the present invention, CD19-CART cells with AAVS1 site-specific integration were successfully constructed in different donor cells, and sequencing verification was performed, with the total positive rate being about 10%-20%, and the knockout rate being about 65%-90%, showing better preparation stability (Figures 11, 12). Based on this, the biological function of D19-CART with AAVS1 site-specific integration was tested. The experimental results showed that CD19-CART cells with AAVS1 site-specific integration had a high viability (Figure 13). Although the electroporation step itself caused a certain degree of cell death, the in vitro proliferation ability of T cells was not significantly affected (Figure 14). After contact with tumor target cells, CD19-CART cells with AAVS1 site-specific integration still proliferated well (Figures 15, 16). Then, the expression of cell surface markers, changes in cell subtypes, secretion of cytokines, etc. were detected. Overall, CD19-CART cells with AAVS1 site-specific integration were able to generate significant responses against tumor cells, similar to CD19-CART cells prepared by lentivirus (Figures 17-19). However, there were some differences between the two. Finally, the tumor-killing ability of CD19-CART cells with AAVS1 site-specific integration was evaluated. In vivo and in vitro results demonstrated that CD19-CART cells prepared by lentivirus had good killing effects against tumor cells, similar to CD19-CART cells prepared by lentivirus (Figures 20, 21).
[0138] Example 3 Using the method of the present invention, construct CD19-CART cells with non-viral PD1 site-specific integration and detect their function Using the method of the present invention, we successfully constructed PD1 site-specific integrated CD19-CART cells with different donor cells, and performed sequencing verification, with the total positive rate being about 10%-30%, the knockout rate being about 80%-95%, and showing better preparation stability (Figures 22, 23). Based on this, we tested the biological function of CD19-CART cells with PD1 site-specific integration. The experimental results showed that after contacting with tumor target cells, CD19-CART cells with PD1 site-specific integration had stronger proliferation ability than CAR-T cells prepared by lentivirus (Figure 24). Similar to CD19-CART cells prepared by lentivirus, CD19-CART cells with PD1 site-specific integration activated the expression of surface markers and secreted cytokines in response to the stimulation of tumor cells, among which the increase in the expression level of CD137 was more obvious (Figure 25), and the increase in the IFN-γ secretion level was more significant (Figure 26). Finally, in vivo and in vitro experiments demonstrated that the PD1 site-specifically integrated CD19-CART cells constructed according to the present invention had stronger tumor-killing ability than CD19-CART cells prepared by lentivirus (Figures 27 and 28).
[0139] In summary, the method of the present invention can be used in combination with site screening to successfully construct CAR-T cells with site-specific integration of AAVS1, PD1, TRAC, and B2M using CRISPR / Cas9 gene editing tools. Compared with the prior art, the present invention proves that the CAR-T cells with site-specific integration prepared by the method of the present invention have a higher positive rate and can function effectively. Compared with the traditional lentivirus preparation method, this technical method can reduce the high cost of using viruses in the preparation process of CAR-T, reduce the safety issues caused by random virus insertion, and improve the uniformity of CAR-T products. In addition, this method can also realize the diverse conversion of CAR-T cells and enhance the anti-tumor ability of CAR-T cells. This example proves the importance and value of the method of providing site-specific integration of exogenous sequences in T cells protected by the present invention, but is not limited to the preparation of CAR-T cells with site-specific integration of AAVS1, PD1, TRAC, and B2M, and can be extended to the site-specific integration of exogenous sequences at other sites and the development of other T cell immunotherapies.
[0140] All documents mentioned in this application are incorporated by reference into this application as if each document was individually incorporated by reference. Furthermore, after reading the above teachings of the present invention, those skilled in the art will be able to make various changes or modifications to the present invention, and these equivalent forms will also fall within the scope defined by the appended claims.
Claims
1. A method for in vitro gene editing of a target site in a cellular genome, comprising: (a) providing a cell to be gene edited; (b) (i) a gene editing enzyme or a nucleic acid encoding the gene editing enzyme, or a first expression vector expressing the gene editing enzyme; and (ii) a gRNA or a second expression vector expressing the gRNA is introduced into the cell to gene edit a target site in the cell genome, and the gRNA guides the gene editing enzyme to site-specifically cleave the target site; Here, the target sequence targeted by the gRNA includes one or more of the sequences shown in SEQ ID NOs: 1 to 6, The method, wherein the gene editing further comprises non-viral site-specific knock-in of donor DNA.
2. 2. The method of claim 1, wherein the gene editing enzyme is selected from the group consisting of a CRISPR-associated protein (Cas) polypeptide, a TALEN enzyme, a ZFN enzyme, or a combination thereof.
3. A gRNA for in vitro gene editing of a target site in a cellular genome, comprising: The gRNA is characterized in that the target sequence targeted by the gRNA includes one or more of the sequences set forth in SEQ ID NOs: 1-6, and the gene editing includes non-viral site-specific knock-in of donor DNA.
4. A composition for in vitro gene editing of a target site in a cellular genome, comprising: (a) a donor DNA that is double-stranded DNA; (b) a gene editing enzyme or a nucleic acid encoding the gene editing enzyme, or a first expression vector expressing the gene editing enzyme; (c) a gRNA or a second expression vector expressing the gRNA; Including, wherein the target sequence targeted by the gRNA comprises one or more of the sequences set forth in SEQ ID NOs: 1-6, and the gene editing comprises non-viral site-specific knock-in of donor DNA.
5. A kit for in vitro gene editing, comprising: i) a first container and a donor DNA, the donor DNA being double-stranded DNA located within the first container; ii) a second container and a gene editing enzyme or a nucleic acid encoding the gene editing enzyme located in the second container, or a first expression vector expressing the gene editing enzyme; iii) a third container and a gRNA or a second expression vector expressing the gRNA located in the third container, wherein the target sequence targeted by the gRNA includes one or more of the sequences set forth in SEQ ID NOs: 1-6, and the gene editing includes non-viral site-specific knock-in of donor DNA.
6. A gene-edited cell produced by the method of claim 1.
7. The cell according to claim 6 for use in tumor immunotherapy or cancer immunotherapy.
Citation Information
Patent Citations
Preparation method for IPS cell having low immunogenicity and capable of realizing apoptosis under induction
CN108998419A
Compositions and methods for immuno-oncology
JP2020513832A
Materials and methods for cell manipulation and their use in immuno-oncology
JP2020519277A
Gene editing t cell and use thereof
WO2019052577A1
Methods, compositions and components for crispr-CAS9 editing of tgfbr2 in t cells for immunotherapy
WO2019089884A2
